These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34957356)

  • 21. Biomechanical origins of inherent tension in fibrin networks.
    Spiewak R; Gosselin A; Merinov D; Litvinov RI; Weisel JW; Tutwiler V; Purohit PK
    J Mech Behav Biomed Mater; 2022 Sep; 133():105328. PubMed ID: 35803206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.
    Whyte CS; Simpson M; Morrow GB; Wallace CA; Mentzer AJ; Knight JC; Shapiro S; Curry N; Bagot CN; Watson H; Cooper JG; Mutch NJ
    J Thromb Haemost; 2022 Oct; 20(10):2394-2406. PubMed ID: 35780481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peroxynitrite may affect fibrinolysis via the reduction of platelet-related fibrinolysis resistance and alteration of clot structure.
    Misztal T; Rusak T; Brańska-Januszewska J; Ostrowska H; Tomasiak M
    Free Radic Biol Med; 2015 Dec; 89():533-47. PubMed ID: 26454084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.
    Sakharov DV; Nagelkerke JF; Rijken DC
    J Biol Chem; 1996 Jan; 271(4):2133-8. PubMed ID: 8567670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
    Wu JH; Siddiqui K; Diamond SL
    Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy.
    Sambola A; García Del Blanco B; Ruiz-Meana M; Francisco J; Barrabés JA; Figueras J; Bañeras J; Otaegui I; Rojas A; Vilardosa Ú; Montaner J; García-Dorado D
    Thromb Haemost; 2016 Jun; 115(6):1129-37. PubMed ID: 26962963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased fibrinolytic potential and morphological changes of fibrin structure in dermatitis herpetiformis.
    Görög A; Németh K; Szabó L; Mayer B; Silló P; Kolev K; Kárpáti S
    J Dermatol Sci; 2016 Oct; 84(1):17-23. PubMed ID: 27440075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of fibrin clot lysis.
    Merrills RJ; Shaw JT
    Biochem J; 1968 Jan; 106(1):101-5. PubMed ID: 4238487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions.
    Petkantchin R; Rousseau A; Eker O; Zouaoui Boudjeltia K; Raynaud F; Chopard B;
    Sci Rep; 2023 Aug; 13(1):13681. PubMed ID: 37608073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorescent microspheres can affect in vitro fibrinolytic outcomes.
    Stoll EG; Cone SJ; Lynch SR; Fuquay AT; Bannish BE; Hudson NE
    PLoS One; 2023; 18(4):e0284163. PubMed ID: 37027378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis.
    Cabrera D; Eizadi Sharifabad M; Ranjbar JA; Telling ND; Harper AGS
    J Thromb Haemost; 2022 Nov; 20(11):2556-2570. PubMed ID: 35950914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of actin filaments on fibrin clot structure and lysis.
    Janmey PA; Lamb JA; Ezzell RM; Hvidt S; Lind SE
    Blood; 1992 Aug; 80(4):928-36. PubMed ID: 1323346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clot retraction facilitates clot lysis.
    Carroll RC; Gerrard JM; Gilliam JM
    Blood; 1981 Jan; 57(1):44-8. PubMed ID: 7448414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
    von dem Borne PA; Meijers JC; Bouma BN
    Blood; 1995 Oct; 86(8):3035-42. PubMed ID: 7579397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma.
    Carr ME; Dent RM; Carr SL
    J Lab Clin Med; 1996 Jul; 128(1):83-8. PubMed ID: 8759939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical determinants of fibrinolysis in single fibrin fibers.
    Bucay I; O'Brien ET; Wulfe SD; Superfine R; Wolberg AS; Falvo MR; Hudson NE
    PLoS One; 2015; 10(2):e0116350. PubMed ID: 25714359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders.
    Nogami K; Matsumoto T; Sasai K; Ogiwara K; Arai N; Shima M
    Br J Haematol; 2019 Nov; 187(4):518-529. PubMed ID: 31335970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.